Clinical Study | Office of Clinical Research

Optune Lua For Malignant Pleural Mesothelioma

Posted Date: Feb 25, 2022

Investigator: Emily Daugherty
Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
Type of Study: Device

Certified user delivery of Optune Lua for use concurrent with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM).

Criteria:

Patients Over 18 Years Old With Unresectable, Locally Advanced Or Metastatic Malignant Pleural Mesothelioma (Mpm)

Keywords:

Tumor-Treating Fields, Mesothelioma

For More Information:

Dr. Emily Daugherty, Md
NULL
daugheec@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List